|View printer-friendly version|
|September 26, 2006 1:58 p.m.|
|Teva Pharmaceutical Industries Ltd. and Protalix Biotherapeutics Ltd. announce a Collaboration Agreement for the development of two Biopharmaceuticals, based on Protalix's recombinant plant cell expression technology|
Jerusalem and Carmiel, Israel, September 26, 2006 - Teva Pharmaceutical Industries Ltd. and Protalix Biotherapeutics Ltd. (Nasdaq: TEVA) have signed a collaboration and licensing agreement for the development of two proteins, using Protalix's plant cell culture platform. The undisclosed proteins, aimed at large-sized markets are not part of Protalix's current product development pipeline.